Reuters logo
Novo Nordisk's Fiasp drug improved overall blood sugar control long-term
September 12, 2017 / 11:03 AM / 10 days ago

Novo Nordisk's Fiasp drug improved overall blood sugar control long-term

COPENHAGEN, Sept 12 (Reuters) - Novo Nordisk said in an analysis presented at the Annual Meeting of the European Association For The Study Of Diabetes:

* Novo’s Fiasp (fast-acting insulin aspart) significantly improved overall blood sugar control in type 1 diabetes long-term (over 52 weeks), compared to conventional insulin aspart (NovoRapid), in new study findings

* Fiasp maintained the significant improvement in overall blood sugar control that was seen in a shorter-term (26 weeks) study period

* “Compared to conventional insulin aspart, Fiasp is a closer match to the natural physiological insulin response, leading to better long-term blood sugar control,” said Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk (Reporting by Stine Jacobsen, editing by Teis Jensen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below